This EMT inhibition is synergistically reinforced through dihydroartemisinin's direct modulation of apoptotic machinery, specifically by reducing anti-apoptotic Bcl-2 expression, elevating pro-apoptotic Bax/Bcl-2 ratio, and activating executioner caspase-3 - constituting a cancer cell apoptosis pathway. The gene discussed is BCL2; the disease is cancer.